139. Back to Basics - Early HER2 Breast Cance...

This episode is the ASCO 2026 Plenary Episode. This week, all of the pivotal, game-changing, life-changing trials are discussed here. Some describe the plenary session as practice-changing, and we will always agree that better treatments with significant improvements in life expe ...  Show more

This week, Josh and Michael's ASCO 2026 coverage looks at "Agents of the Future", trials of intrigue, promise and potential beyond its status. This episode also sheds light on more orphan status cancers like head and neck cancer, basket cohort studies, resistant EGFR lung cancer, ...  Show more

Join Drs Kevin Kalinsky and Jennifer Litton as they discuss hereditary breast cancer, genetic testing, and therapeutic implications. Relevant disclosures can be found with the episode show notes on Medscape ( https://www.medscape.com/viewarticle/991258). The topics and discussions ...  Show more

Patients with metastatic breast cancer whose tumors express low levels of HER2 are generally classified and treated as having HER2-negative disease.

However, Dr. Shanu Modi of the Memorial Sloan Kettering Cancer Center and a group of international collaborators explored ...

Breast cancer is one of the most studied and high-profile cancers, and yet we still have so much to learn. While we have come such a long way and so many lives have been saved by advances in research, there’s still some breast cancers that are aggressive and don’t respond to trea ...  Show more

Drs. Hope Rugo and Nancy Davidson discuss the next generation of endocrine therapy in hormone receptor-positive breast cancer – SERDs, SERMs, CERANs, and PROTACs – and challenges relating to the optimal sequence of therapeutic options.